Breakthrough in Lung Cancer Gene Therapy: New Nanoparticle Formulation Shows Promise

Strategic Insights -

Researchers from the Tianjin University of Science and Technology have developed a novel lung-targeted cancer gene therapy using docetaxel and TUBB3-siRNA-loaded lipid nanoparticles. This innovative formulation addresses the need for specialized treatments with strong lung targeting capabilities, currently lacking in the field. The study's findings suggest that the nanocarriers, converted into inhalable dry powders through spray freeze-drying, exhibit excellent biocompatibility and sustained-release properties, making them an efficient delivery device for targeted therapy of lung cancer.

Key Takeaways:

  • The study highlights the significance of lung cancer as the most prevalent and deadly tumor globally, with a poor prognosis due to drug resistance.
  • The novel lung-targeted cancer gene therapy formulation combines chemotherapy (docetaxel) and RNA interference (RNAi) (TUBB3-siRNA) for lung cancer treatment.
  • Lipid nanoparticles (LNPs) were used as nanocarriers suitable for nucleic acid delivery, converted into inhalable dry powders through spray freeze-drying (SFD).
  • The geometric particle size distribution and median mass aerodynamic diameter (MMAD) of the inhalable powders were found suitable for pulmonary deposition.
  • Experiments showed that TUBB3/DTX-LNPs had low cytotoxicity and good biocompatibility with BEAS-2B cells but strongly inhibited H460 cells.
  • Differences in apoptosis induced by fresh LNPs and rehydrated LNP (SFD) indicate that the SFD process preserves normal cell viability while maintaining tumor inhibition.
  • A specialized single-dose prefilled device was developed, featuring four symmetrically configured orifices, which achieved a high dry powder emptying rate of 95-100%.
  • The research demonstrated the lung-targeting efficacy and sustained-release properties of the formulation, providing exciting prospects for targeted therapy of lung cancer.

Statistics:

  • Size of fresh and rehydrated LNP (SFD): below 200 nm
  • z-potential of fresh and rehydrated LNP (SFD): near 0 mV
  • Geometric particle size distribution (D50): 1.99-5.90 mm
  • Median mass aerodynamic diameter (MMAD): 2.61 ± 0.32 mm
  • High dry powder emptying rate achieved: 95-100%

Sources:

  • TUBB3/DTX LNPs Dry Powder Inhaler and an Efficient Delivery Device for Targeted Therapy of Lung Cancer. ACS Applied Materials & Interfaces, 2025.
  • NewsRx. Study Data from Tianjin University of Science and Technology Update Understanding of Cancer Gene Therapy (TUBB3/DTX LNPs Dry Powder Inhaler and an Efficient Delivery Device for Targeted Therapy of Lung Cancer). Cancer Weekly. August 12, 2025; p 99.